On 7 February 2024, global contract development and manufacturing company Samsung Biologics announced that it has partnered with LegoChem Biosciences for antibody-drug conjugate (ADC) development and manufacturing. Under the agreement, Samsung Biologics will provide antibody development and drug substance manufacturing services as part of LegoChem Bioscience’s ADC program designed to treat solid tumours. LegoChem is aiming to submit an Investigational New Drug (IND) application to the FDA in the first half of 2025.
Samsung Biologics also reports that it is on track to complete a dedicated ADC facility in South Korea in 2024. Two weeks ago, Samsung Biologics revealed in its Q4 2024 Earnings its record high operating profit of over ₩1T for 2023.